Drug candidate daxibotulinumtoxinA (RT002, Revance Therapeutics) started phase 3 SAKURA trials in December 2016 to evaluate single injections for the treatment of glabellar lines. Why it is different from first-gen neurotoxins.
Click to contact the editorial team. Click to contact the sales team.
Part of the
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
